Search results
- 1.0200Add to watchlist-0.0600 (-5.56%)At close: Wed. Jun 5, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Pre-Market Time
- Open1.0400High1.0700Low0.9802
- Mkt Cap37.65MP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close1.080052 Wk. Low0.490052 Wk. High3.2500
Related stocks
Find the latest Xilio Therapeutics, Inc. (XLO) stock quote, history, news and other vital information to help you with your stock trading and investing.
- Profile
See the company profile for Xilio Therapeutics, Inc. (XLO)...
- Chart
Interactive Chart for Xilio Therapeutics, Inc. (XLO),...
- Sustainability
See Xilio Therapeutics, Inc. (XLO) Environment, Social and...
- Options
View the basic XLO option chain and compare options of Xilio...
- Holders
Find out the direct holders, institutional holders and...
- Historical Data
Discover historical prices for XLO stock on Yahoo Finance....
- Profile
May 22, 2024 · XLO is the ticker symbol for Xilio Therapeutics Inc., a biotechnology company that develops immunotherapies for cancer. The stock price, performance, financials, news, and competitors are shown on the web page.
Get the latest Xilio Therapeutics Inc (XLO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
6 days ago · Xilio Therapeutics (XLO) (Real Time Quote from BATS) $1.05 USD. -0.03 (-2.78%) Updated Jun 5, 2024 11:58 AM ET. Add to portfolio. Zacks Rank: 2-Buy 2. Style Scores: F Value | B Growth | F...
5 days ago · Xilio Therapeutics is a biotech company developing tumor-activated immuno-oncology therapies. See its stock price, news, financials, statistics, forecast, profile and chart on Stock Analysis.
Get the latest bid and ask price, market cap, and news for Xilio Therapeutics, Inc. Common Stock (XLO) on Nasdaq. Learn how to analyze stocks based on your investment priorities and access data and analytics via cloud APIs.
View the latest Xilio Therapeutics Inc. (XLO) stock price, news, historical charts, analyst ratings and financial information from WSJ.